336 related articles for article (PubMed ID: 28241065)
1. Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.
Schrantee A; Tremoleda JL; Wylezinska-Arridge M; Bouet V; Hesseling P; Meerhoff GF; de Bruin KM; Koeleman J; Freret T; Boulouard M; Desfosses E; Galineau L; Gozzi A; Dauphin F; Gsell W; Booij J; Lucassen PJ; Reneman L
PLoS One; 2017; 12(2):e0172776. PubMed ID: 28241065
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations.
Calipari ES; Ferris MJ; Melchior JR; Bermejo K; Salahpour A; Roberts DC; Jones SR
Addict Biol; 2014 Mar; 19(2):145-55. PubMed ID: 22458761
[TBL] [Abstract][Full Text] [Related]
3. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.
Wagner AK; Drewencki LL; Chen X; Santos FR; Khan AS; Harun R; Torres GE; Michael AC; Dixon CE
J Neurochem; 2009 Feb; 108(4):986-97. PubMed ID: 19077052
[TBL] [Abstract][Full Text] [Related]
4. Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate.
Ahn S; Phillips AG
ACS Chem Neurosci; 2013 May; 4(5):817-24. PubMed ID: 23586444
[TBL] [Abstract][Full Text] [Related]
5. Differential influence of dopamine transport rate on the potencies of cocaine, amphetamine, and methylphenidate.
Calipari ES; Ferris MJ; Siciliano CA; Jones SR
ACS Chem Neurosci; 2015 Jan; 6(1):155-62. PubMed ID: 25474655
[TBL] [Abstract][Full Text] [Related]
6. Differences between electrically-, ritalin- and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of Attention-Deficit Hyperactivity Disorder.
Russell V; de Villiers A; Sagvolden T; Lamm M; Taljaard J
Behav Brain Res; 1998 Jul; 94(1):163-71. PubMed ID: 9708847
[TBL] [Abstract][Full Text] [Related]
7. Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls.
Schrantee A; Ferguson B; Stoffers D; Booij J; Rombouts S; Reneman L
Brain Imaging Behav; 2016 Jun; 10(2):548-58. PubMed ID: 26149196
[TBL] [Abstract][Full Text] [Related]
8. Monoaminergic dysfunction in recreational users of dexamphetamine.
Schouw ML; Caan MW; Geurts HM; Schmand B; Booij J; Nederveen AJ; Reneman L
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1491-502. PubMed ID: 23415394
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses.
Ren J; Xu H; Choi JK; Jenkins BG; Chen YI
Synapse; 2009 Sep; 63(9):764-72. PubMed ID: 19484725
[TBL] [Abstract][Full Text] [Related]
10. Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism.
Owens WA; Williams JM; Saunders C; Avison MJ; Galli A; Daws LC
J Neurosci; 2012 Feb; 32(8):2637-47. PubMed ID: 22357848
[TBL] [Abstract][Full Text] [Related]
11. Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats.
Robison LS; Ananth M; Hadjiargyrou M; Komatsu DE; Thanos PK
J Neural Transm (Vienna); 2017 May; 124(5):655-667. PubMed ID: 28116523
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological MRI response to a selective dopamine transporter inhibitor, GBR12909, in awake and anesthetized rats.
Kashiwagi Y; Rokugawa T; Yamada T; Obata A; Watabe H; Yoshioka Y; Abe K
Synapse; 2015 Apr; 69(4):203-12. PubMed ID: 25612063
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic neuroimaging of the ontogeny of dopamine receptor function.
Chen YI; Choi JK; Xu H; Ren J; Andersen SL; Jenkins BG
Dev Neurosci; 2010 Jul; 32(2):125-38. PubMed ID: 20523024
[TBL] [Abstract][Full Text] [Related]
14. Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics.
Wooters TE; Bardo MT; Dwoskin LP; Midde NM; Gomez AM; Mactutus CF; Booze RM; Zhu J
Behav Brain Res; 2011 May; 219(1):98-107. PubMed ID: 21219939
[TBL] [Abstract][Full Text] [Related]
15. The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD.
Simchon Y; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2010 Oct; 20(10):714-20. PubMed ID: 20493667
[TBL] [Abstract][Full Text] [Related]
16. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM
Synapse; 2002 Mar; 43(3):181-7. PubMed ID: 11793423
[TBL] [Abstract][Full Text] [Related]
17. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic system dysfunction in recreational dexamphetamine users.
Schrantee A; Václavů L; Heijtel DF; Caan MW; Gsell W; Lucassen PJ; Nederveen AJ; Booij J; Reneman L
Neuropsychopharmacology; 2015 Mar; 40(5):1172-80. PubMed ID: 25394786
[TBL] [Abstract][Full Text] [Related]
19. Amphetamine self-administration attenuates dopamine D2 autoreceptor function.
Calipari ES; Sun H; Eldeeb K; Luessen DJ; Feng X; Howlett AC; Jones SR; Chen R
Neuropsychopharmacology; 2014 Jul; 39(8):1833-42. PubMed ID: 24513972
[TBL] [Abstract][Full Text] [Related]
20. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging.
Chen YC; Choi JK; Andersen SL; Rosen BR; Jenkins BG
Psychopharmacology (Berl); 2005 Aug; 180(4):705-15. PubMed ID: 15536545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
